Gyre Therapeutics completed its acquisition of Cullgen in an all-stock deal valued at about $300 million, creating a fully integrated biopharmaceutical company with operations in the U.S. and China. The combined company now has a commercial product, ETUARY®, for lung fibrosis in China, and a robust pipeline including F351 for liver fibrosis and targeted protein degraders from Cullgen. This strategic move strengthens Gyre's leadership and innovation capabilities, supporting future global growth and expanding treatment options for fibrosis and inflammatory diseases. The company is advancing multiple late-stage clinical trials and exploring international development opportunities for its key drug candidates.
Air Comm, a leading provider of wireless communication and security technology, has opened a new office in Farmers Branch, Texas, expanding its presence in the Dallas-Fort Worth area. This new location enhances Air Comm's ability to offer faster loca...
Metallium Limited has successfully operated three Flash Joule Heating units simultaneously at its Texas facility, marking a key milestone in scaling its proprietary technology. The operation achieved 83% availability and nearly 100% utilization, exce...
iRhythm Holdings disclosed a cybersecurity breach involving unauthorized access to data on third-party business applications. Hackers claimed to have sensitive company and patient information and demanded payment to avoid public release. The company ...
On June 15, 2026, BlackRock, Inc. and its funds reduced their total holdings in Orion Corporation to below 5% of the company's shares and voting rights. This change was disclosed under the Finnish Securities Market Act, indicating a decrease from a p...
BlackRock, Inc. has reported that its direct and indirect ownership in Orion Oyj has dropped below the 5% threshold as of June 15, 2026. This change requires a formal disclosure under Finnish securities law. The reduction in BlackRock's stake may aff...
